[Atrial Fibrillation and Diabetes Mellitus: the Control of Thromboembolic Risk]

Area of Science:

• Cardiology
• Endocrinology
• Pharmacology

Background:

• Atrial fibrillation (AF) is a common comorbidity in patients with diabetes mellitus (DM).
• Diabetic patients with AF exhibit a more severe disease course, with higher rates of hypertension, kidney disease, heart failure, and stroke.
• The interplay between DM and AF exacerbates both conditions.

Purpose of the Study:

• To discuss the mechanisms underlying the mutual aggravation of DM and AF.
• To review risk stratification scales for bleeding in AF patients.
• To evaluate the role and efficacy of anticoagulants in patients with both AF and DM.

Main Methods:

• Meta-analysis of 16 randomized clinical studies.
• Inclusion of 9,874 patients with AF and DM.
• Review of current antithrombotic therapies and bleeding risk scales (CHADS2, CHA2DS2‑VASc, HAS-BLED).

Main Results:

• Oral anticoagulants demonstrated a 62% relative risk reduction in stroke compared to placebo.
• Patients with both AF and DM were younger and had more comorbidities.
• Rivaroxaban is a well-studied oral factor Xa inhibitor for AF and DM patients, offering an alternative to warfarin.

Conclusions:

• Antithrombotic therapies are effective in preventing complications for patients with AF and DM.
• Rivaroxaban is a viable and well-researched anticoagulant option for this patient population.
• Understanding the mechanisms and risks is crucial for managing comorbid AF and DM.